Aptevo Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 40
- Market Cap
- -
- Introduction
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and AD...
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT06634394
ALG.APV-527 First-in-human Study
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT05934539
- Locations
- 🇺🇸
Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Aptevo Therapeutics
- Registration Number
- NCT04973618
Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT03768219
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 35
- Registration Number
- NCT02262910
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇺🇸University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Phase 1b Safety and Efficacy Study of TRU-016
- Conditions
- Interventions
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 87
- Registration Number
- NCT01644253
- Locations
- 🇺🇸
Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸Greenville Health System, Greenville, South Carolina, United States
🇺🇸Swedish Cancer Institute,1221 Madison St., Seattle, Washington, United States
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT01317901
- Locations
- 🇺🇸
Site Reference ID/Investigator# 61523, Omaha, Nebraska, United States
🇺🇸Site Reference ID/Investigator# 61542, Augusta, Georgia, United States
🇺🇸Site Reference ID/Investigator# 61522, Hackensack, New Jersey, United States
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 79
- Registration Number
- NCT01188681
- Locations
- 🇪🇸
For additional information regarding sites for this trial call (919) 465-4648, Navarre, Spain
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 96
- Registration Number
- NCT00614042
- Locations
- 🇺🇸
For additional information regarding sites for this trial call 919-319-9374, Seattle, Washington, United States